Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar ○
found
a story from CNBC ⚠️ › World News
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.